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Human group‑specific component protein (Gc protein) is a multifunctional serum protein which has 
three common allelic variants, Gc1F, Gc1S and Gc2 in humans. Gc1 contains an O‑linked trisaccharide 
[sialic acid‑galactose‑N‑acetylgalactosamine (GalNAc)] on the  threonine420  (Thr420) residue and can 
be converted to a potent macrophage activating factor (GcMAF) by selective removal of sialic acid 
and galactose, leaving GalNAc at  Thr420. In contrast, Gc2 is not glycosylated. GcMAF is considered a 
promising candidate for immunotherapy and antiangiogenic therapy of cancers and has attracted 
great interest, but it remains difficult to compare findings among research groups because different 
procedures have been used to prepare GcMAF. Here, we present a simple, practical method to prepare 
high‑quality GcMAF by overexpressing Gc‑protein in a serum‑free suspension culture of ExpiCHO‑S 
cells, without the need for a de‑glycosylation step. We believe this protocol is suitable for large‑scale 
production of GcMAF for functional analysis and clinical testing.
Human group-specific component protein (Gc), also known as Gc globulin (GcG) or vitamin D binding protein 
(DBP), is a 458-amino acid protein with an unmodified mass of 51.2 kDa. Gc protein is mainly synthesized in 
liver and is present at a high level in blood/plasma (300–600 mg/L), and at lower concentrations in colostrum 
and  milk1,2. It was first described in  19593, and three common allelic variants, Gc1F, Gc1S and Gc2 were subse-
quently identified in the human population. Relative to the Gc1F protein, Gc1S contains a glutamate residue in 
place of aspartate at position 416 (D416E mutation), while Gc2 contains a lysine residue in place of threonine 
at position 420 (T420K mutation)4–6. Gc protein has at least four distinct molecular functions. Namely, (1) Gc 
protein contains a single vitamin D-binding site at N-terminal domain 1, enabling it to work as a carrier protein 
of vitamin D metabolites in  blood2,7–9, (2) it has a role in the circulating actin scavenger system, preventing 
narrowing of small blood vessels by binding to monomeric actin (G-actin) released from damaged cells in the 
events of cell injury and  lysis10,11, (3) it is a precursor of a potent activator of macrophages (GcMAF, Gc-derived 
macrophage activating factor) and  osteoclasts12–15, and (4) it serves as a chemotactic cofactor for C5a by interact-
ing with cell-surface proteins of  neutrophils16,17.
The C-terminal end of Gc1 (domain III) harbors a single glycosylation site. The carbohydrate structure 
was firstly elucidated by analysis of the products generated by treatment with several glycolytic  enzymes12,18,19, 
and it was reported that Gc1 contains an O-linked trisaccharide with GalNAc attached to  Thr420, followed by 
a galactose moiety, and a sialic acid (in Gc1F) or mannose moiety (in Gc1S). Gc2, which lacks this threonine 
residue, was thought to have only a disaccharide moiety composed of GalNAc and galactose, although more than 
90% of Gc2 is present as a non-glycosylated form in  humans12,18,19. However, current detailed glycan structural 
analyses using glycosidase treatment and mass  spectrometry6,20–22 indicated that (1) Gc1F and Gc1S proteins 
have the same linear trisaccharide, sialic acid-galactose-GalNAc, on the  Thr420 residue (Fig. 1 Model B)23 and (2) 
substitution of a lysine residue at the position corresponding to  Thr420 in Gc2 prevents this isoform from being 
glycosylated at that position, and thus Gc2 is not glycosylated (Fig. 1). These conclusions are supported by the 
finding that Gc1 from cancer patients contains the same trisaccharide as Gc1 from healthy volunteers, namely, 
sialic acid-galactose-GalNAc-Thr42024.
Gc proteins are converted into GcMAF via de-glycosylation; specifically, it has been hypothesized that inflam-
mation results in selective hydrolysis of galactose and sialic acid of Gc1 proteins by β-galactosidase of stimulated 
B lymphocytes and sialidase of T  lymphocytes13,25,26, leaving GalNAc covalently attached to the threonine residue 
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(Fig. 1). Reported activities of GcMAF include macrophage  activation27, anti-angiogenesis  activity28–30, and anti-
tumor  activity31–33. Indeed, human blood-derived GcMAF has been reported to be effective against metastatic 
colorectal, metastatic breast and prostate  cancers34–36. The medication of GcMAF is, therefore, potential options 
for immunotherapy and antiangiogenic therapy against cancers. However, biological studies and clinical trials of 
GcMAF have yielded inconsistent results, probably because most laboratories and cancer clinics have produced 
their own GcMAFs using different procedures, even though all are based on sequential de-glycosylation of Gc 
proteins prepared from human blood. Thus, there is a need for methodology to provide a consistent product on 
a large scale for further studies.
Here, we present a practical method to prepare high-quality GcMAF by overexpressing Gc protein in a 
serum-free suspension culture of ExpiCHO-S cells, without the need for a de-glycosylation step. The synthesized 
GcMAF can be purified by a single step of vitamin D affinity column chromatography. This simple methodology 
enables the production of large amounts of high-quality GcMAF, and should greatly advance functional analyses 
and further clinical evaluation of GcMAF.
Results
Expression of Gc1F in CHO cells. The Gc1F-His expression vector (pcDNA3.4-TOPOGc1F-His) (Sup-
plementary Figs.  1 and 2) was transfected into CHO cells using lipofectamine 2000, and the cells were cul-
tured for 3–4 days. The supernatant was applied to a His Trap HP column, which was washed with binding 
buffer and eluted with elution buffer solution. The eluate was desalted by dialysis against 50  mM sodium 
phosphate-buffered saline pH 7.4, and an aliquot of the desalted fraction was de-glycosylated with β-d-
Figure 1.  Structure of Gc protein and its conversion to GcMAF. Yamamoto et al. proposed (Model A) for the 
structure of DBP/Gc1F protein and its conversion to  GcMAF25. In this model, GalNAc is covalently bound to 
 Thr420 of the Gc1F protein and galactose and sialic acid are bound to GalNAc in a Y-branched arrangement. 
Therefore, removal of galactose and sialic acid exposes the GalNAc moiety and leads to the formation of 
activated GcMAF. However, Ravnsborg et al. recently proposed a linear model (Model B) based on mass 
spectrometry  findings23. In this model, the three sugar moieties attached to threonine 420 are arranged in a 
linear fashion with GalNAc covalently bound to threonine, and galactose and sialic acid attached to the GalNAc 
in this order. Non-glycosylated Gc2 is also illustrated based on current mass spectrometry findings.
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galactosidase and sialidase. These preparations were subjected to SDS gel electrophoresis, transferred to a mem-
brane, and stained with anti-human Gc antibody, anti-His antibody and biotin-conjugated Helix promatia (HPA) 
lectin which roughly reacts to GalNAc. As expected, the expressed protein in the desalted fraction was detected 
with the antibodies against Gc and His (Fig. 2A), but not with biotin-conjugated HPA lectin (Fig. 2B (−)). How-
ever, the protein in the de-glycosylated fraction (Fig. 2B (+))was detected with HPA lectin, suggesting that Gc1F-
His protein bearing O-linked trisaccharide (i.e., Sialic acid-Galactose-GalNAc-Thr420)20–23 was synthesized in 
CHO cells, and that sialic acid and galactose were removed by the de-glycosylation treatment (Fig. 2B (+)). This 
result is consistent with reports that Gc protein prepared from human blood can be converted to HPA lectin-
reactive GcMAF by treatment with β-d-galactosidase and  sialidase34–36. To examine whether the protein synthe-
sized in CHO cells is N-glycosylated, the desalted His-tagged Gc1F was treated with PNGase and subjected to 
SDS gel electrophoresis (Fig. 2C). The bands marked by arrowheads showed similar mobilities, suggesting that 
Gc protein synthesized in CHO cells was not N-glycosylated.
Production of HPA lectin‑reactive Gc proteins without a de‑glycosylation step. Based on the 
above observation, we attempted to establish a standard procedure for large-scale preparation of Gc-protein 
using serum-free suspension-cultured ExpiCHO-S cells, because this approach has been widely used for large-
scale preparation of proteins. Briefly, ExpiCHO-S cells were pre-cultured in serum-free suspension culture 
medium for 2 days. Expression vector DNA (pcDNA3.4-TOPOGc1F-His) (Supplementary Figs. 1 and 2) was trans-
fected into the pre-cultured cells using Lipofectamine 2000 and culture was continued for 7–8 days; the survival 
rate of cells gradually decreased and fell below 90% (the recommended criterion to stop culture) at culture days 
7 or 8. The culture supernatant was collected by centrifugation at 10,000 × g for 15 min, and applied to a Ni–NTA 
agarose column. The eluate was desalted by dialysis against phosphate buffer, and then de-glycosylated with 
β-d-galactosidase and sialidase. The de-salted and de-glycosylated fractions were each characterized by Western 
blot analysis (Fig. 3).
To our surprise, Gc1F-His expressed in ExpiCHO-S cells was detected not only with anti-Gc antibody 
(Fig. 3A, left panel), but also with HPA lectin, irrespective of treatment with or without de-glycosylation enzymes 
Figure 2.  Characterization of Gc1F synthesized in CHO cells. Culture supernatants were adjusted to the 
composition and pH of the binding buffer of His Trap HP  (Ni2+ pre-charged) column chromatography. The 
samples were applied to the column, which was washed and then eluted with elution buffer. The eluate was 
desalted by dialysis against 50 mM sodium phosphate pH 7.0 (desalted fraction). The desalted fraction was 
subjected to 5–20% SDS polyacrylamide gel and bands were blotted onto PVDF membrane. Anti-Gc antibody 
(A, left panel) and anti-His antibody (A; right panel) were used to detect His-tagged Gc1F and visualized 
by an enhanced chemiluminescence detection system. Aliquots of desalted His-tagged Gc1F (B (−)) and 
a sample treated with β-d-galactosidase and sialidase (B (+)) were characterized by HPA-lectin blotting. 
HPA-lectin-reactive Gc1F is indicated by an arrowhead (B (+)). Extra bands indicated by * are unknown 
HPA-lectin-reactive protein(s) that were removed during vitamin D affinity column chromatography (see 
Fig. 4A). N-Glycosylation of Gc-1F synthesized in CHO cells was analyzed (C). Desalted His-tagged Gc1F ((C) 
no-incubation) was treated with PNGase (C (+)) or incubated without PNGase (C (−)) and subjected to SDS gel 
electrophoresis. Full-length blots are included in a Supplementary Fig. 4.
4
Vol:.(1234567890)
Scientific Reports |        (2020) 10:19122  | https://doi.org/10.1038/s41598-020-75571-y
www.nature.com/scientificreports/
(Fig. 3A, right panel). Furthermore, the reactivity to HPA lectin was not further increased by de-glycosylation 
treatment (Fig. 3A, right panel), suggesting that HPA lectin-reactive saccharide (GalNAc-Thr420) was attached 
to almost all of the Gc1F-His synthesized in ExpiCHO-S cells under serum free suspension-culture conditions.
We next examined whether the above finding is specific to ExpiCHO-S cells. To test this, we synthesized 
GcIF-His in Expi293-F cells, another type of cells available for serum-free suspension culture. As shown in 
Fig. 3B, Gc1F-His expressed in Expi293-F cells was detected with both anti-Gc antibody (data not shown) and 
biotin-conjugated HPA lectin irrespective of treatment with or without de-glycosylation enzymes, suggesting 
that HPA lectin-reactive saccharide (GalNAc-Thr420) was present on the expressed protein.
Since three allelic variants, Gc1F, Gc1S and Gc2, are found in  humans4–6, we next examined whether HPA 
lectin-reactive forms of Gc1S and Gc2 are also synthesized under serum-free suspension culture conditions, by 
transfecting pcDNA3.4-TOPOGc1S-His and pcDNA3.4-TOPOGc2-His (Supplementary Fig. 1) into ExpiCHO-S cells. 
As shown in Fig. 4A, Gc1S-His was detected with biotin-conjugated HPA lectin, irrespective of treatment with 
or without de-glycosylation enzymes. However, Gc2-His was not detected by HPA lectin even after treatment 
with de-glycosylation enzymes.
Since many lectins only display moderate specificity, we confirmed the above results by using other lectins: 
biotinylated Vicia villosa (VVA) lectin, biotinylated Maackia amurensis (MAL-II) lectin II and biotinylated 
peanut (PNA) lectin. As expected, Gc1F and Gc1S reacted strongly with HPA and VVA lectins, which respond 
to GalNAc/Tn, but scarcely reacted with PNA and MALII lectins, which show a preference for Gal-GalNAc/T 
disaccharide and sialic acid/STn/ST, respectively (Fig. 4B). The reactions of Gc2 with HPA, VVA, PNA, and 
MALII lectins were negligible (Fig. 4B). Taken together, these results may indicate that Gc1F and Gc1S produced 
in ExpiCHO-S cells are glycosylated with GalNAc at  Thr420, while Gc2 is not glycosylated.
Purification of Gc proteins by vitamin D affinity column chromatography. Gc1 and Gc2 proteins 
synthesized in ExpiCHO-S cells were purified by His-tag column chromatography and vitamin D affinity col-
umn chromatography (Fig. 5A–D). The Gc1 and Gc2 proteins were each purified as a single band of 53,000 Da. 
We next tested whether the His-tag column chromatography step could be skipped; if so, it should be feasible to 
produce native Gc protein without the extra tag sequence. To examine this, we synthesized tag-less mouse Gc 
protein (Supplementary Fig. 1C, pcDNA3.4-TOPOmouse-Gc) in ExpiCHO-S cells and purified the product by a 
single step of vitamin D affinity column chromatography. The product was detected as a single band of 52,000 Da 
(Fig. 5E) and confirmed to be HPA lectin-reactive.
Figure 3.  Characterization of Gc1F synthesized in ExpiCHO-S cells and in Expi293-F cells. (A) Three samples 
of Gc1F-His independently synthesized in ExpiCHO-S cells were characterized using anti-Gc antibody 
(left panel). Sugar modifications of His-tagged Gc1F alone (−) and after treatment with β-d-galactosidase 
and sialidase (+) were analyzed by biotin-conjugated HPA-lectin blotting (right panel). (B) Gc1F-His was 
synthesized in Expi293-F cells under serum-free suspension culture conditions. Sugar modifications of 
Gc1F-His alone (−) and after treatment with β-d-galactosidase and sialidase (+) were characterized by biotin-
conjugated HPA-lectin blotting. Full-length blots are included in a Supplementary Fig. 4.
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Phagocytosis assay of Gc proteins synthesized in ExpiCHO‑S cells. We next analyzed the phago-
cytosis activation activity of Gc proteins synthesized in ExpiCHO-S cells. U937 cells were grown in RPMI-1640 
medium and differentiated into macrophage-like cells by means of TPA treatment. Then, U937 cell-derived mac-
rophages were activated by exposure to purified Gc proteins and LPS (a typical macrophage-activating chemi-
cal). Since the phagocytic activity of macrophages induced by Gc1F derived GcMAF is significantly increased 
at the concentration of 10 ng/ml37, we evaluated the average phagocytosis index (API) of the Gc proteins at this 
concentration. As shown in Fig. 6A, API was increased by the addition of Gc proteins and the activation levels 
of Gc1F and Gc1S were equivalent with that of LPS, used as a positive control, though the activation level of 
Gc2 was a little lower. We next examined the effect of de-glycosylation by comparing the macrophage-activating 
activities of Gc-1F from ExpiCHO-S with a truncated structure (GalNAc-Thr420, Positive control), Gc-1F from 
CHO with an elongated glycoform (Trisaccharide-Thr420) and Gc-1F from CHO with a truncated glycoform 
(after de-glycosylation reaction, GalNAc-Thr420). As shown in Fig. 6B, the APIs of Gc-1F from ExpiCHO-S with 
a truncated structure and Gc-1F from CHO with a truncated glycoform were similarly increased, whereas the 
activation by Gc-1F from CHO with an elongated glycoform was negligible, suggesting that Gc-1F from CHO 
is activated by de-glycosylation. We further confirmed that API was dose-dependently increased up to 100 ng/
ml for Gc1F, Gc1S and Gc2 (Fig. 6C-1, -2, -3). The actual values obtained in the macrophage activation assay are 
given in Supplementary Table 1.
Discussion
In this work, we present a simple procedure for the large-scale preparation of the phagocytosis-activation active 
form of Gc, namely GcMAF. In humans, the Gc1F and Gc1S allelic variants are synthesized as a phagocytosis-
activation inactive and HPA lectin nonreactive forms in the liver, and are converted to phagocytosis-activation 
active and HPA lectin reactive forms by cleavage of the O-linked sialic acid-galactose-GalNAc-Thr420 to afford 
the monosaccharide (GalNAc-Thr420). In accordance with this, we found that the phagocytosis-activation inactive 
Figure 4.  Characterization of Gc1S, Gc2 and Gc1F synthesized by ExpiCHO-S cells in serum-free suspension 
culture. Gc1S and Gc2 were synthesized by ExpiCHO-S cells transfected with pcDNA3.4-TOPOGc1S-His or 
pcDNA3.4-TOPOGc2-His (Supplementary Fig. 1) in serum-free suspension culture. Gc1S and Gc2 were purified 
by His Trap HP  (Ni2+ pre-charged) column chromatography and desalted by dialysis against 50 mM sodium 
phosphate pH 7.0 (desalted fraction). Sugar moieties of the desalted fraction alone (−) and after treatment with 
β-d-galactosidase and sialidase (+) were analyzed by blotting with biotin-conjugated HPA-lectin (arrowhead). 
Purified Gc1F was analyzed as a control. Gc1S, Gc2 and Gc1F reacted with anti-Gc antibody (lower column). 
Extra bands indicated by * were unknown HPA-lectin reactive proteins that became undetectable after vitamin 
D affinity column chromatography (see lanes 1F+, 1F−). (B) Gc1F, Gc1S and Gc2 synthesized by ExpiCHO-S 
cells in serum-free suspension culture were purified by His Trap HP  (Ni2+ pre-charged) column chromatography 
and Vitamin D affinity column chromatography, and then desalted by dialysis against 50 mM sodium phosphate 
pH 7.0 (desalted fraction). Sugar moieties of the desalted fraction without treatment (−) and after treatment 
with β-d-galactosidase and sialidase (+) were analyzed by blotting with HPA, VVA, PNA, or MALII lectins as 
indicated. Full-length blots are included in a Supplementary Fig. 4.
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and HPA lectin nonreactive form of Gc1F was synthesized in CHO cells and converted to phagocytosis-activation 
active and HPA-lectin reactive form by the action of de-glycosylation enzymes (β-d-galactosidase and sialidase) 
(Figs. 2B, 6C). However, to our surprise, phagocytosis-activation active and HPA lectin reactive Gc1F was 
directly synthesized in ExpiCHO-S cells and in Expi293-F cells under serum-free suspension culture conditions. 
Furthermore, Gc1S and Gc2 were also synthesized as phagocytosis-activation active forms in ExpiCHO-S cells 
(Fig. 6). As expected, Gc1F and Gc1S were reactive with HPA and VVA-lectins. However, Gc2 (T420K muta-
tion) was not. This suggests that (1) HPA-lectin-reactive saccharide may be not essential for the phagocytosis-
activation activity of Gc2 protein, at least in vitro, and (2) if so, Gc2 synthesized in ExpiCHO-S cells may act as 
a phagocytosis-activation factor via a mechanism not involving GalNAc. This may support the hypothesis that 
the presence or absence of GalNAc at  Thr420 of Gc protein is irrelevant in determining immune competency 
and/or cancer  risk38, and may also be consistent with the fact that the risk of cancer in Gc2-2 homozygotes is 
decreased rather than increased, even though they are unable to produce GcMAF containing GalNAc-Thr42039.
A stereo view of the overall fold structure of human Gc  protein40. indicates that amino acids 418–420, includ-
ing the glycosylation site, are located in the vicinity of the loop-helix (H3) structure, and the sugar moiety seems 
to be located on the exterior of a globular conformation of H3 (Supplementary Fig. 3)41. Thus, the truncated 
sugar moiety (GalNAc-Thr420) could be recognized by a putative receptor protein on the cell surface of mac-
rophages and might initiate complex formation between Gc1 protein and the putative receptor (Supplementary 
Fig. 3B). However, the recognition/interaction between the sugar moiety and putative receptor alone might be 
not sufficient for functional/stable complex formation and protein–protein interaction between Gc1 protein 
and the putative receptor would be required for the formation of a functional/stable complex to transduce 
the macrophage activation signal (Supplementary Fig. 3B). Thus, in this system, GalNAc-Thr420 may function 
as a marker for molecular recognition by the putative receptor, triggering the protein–protein interaction. In 
contrast, the trisaccharide attached to  Thr420 is not recognized by the putative receptor and thus cannot initiate 
protein–protein interaction. Furthermore, the trisaccharide attached to  Thr420 may interfere with the interac-
tion between Gc1 protein and the putative receptor (Supplementary Fig. 3A). This might be the reason why the 
truncation of sialic acid and galactose is required for the conversion of inactive Gc protein to active GcMAF. 
Since Gc2 has no sugar chain, such interference with protein–protein interaction between Gc2 and the putative 
receptor protein would not occur (Supplementary Fig. 3C). Although it is still unclear how the putative receptor 
can recognize Gc2 without GalNAc on  Thr420, the amino acid substitution (T420K mutation) in Gc2 might favor 
interaction with the putative receptor and if so, Gc2 itself might be always functional, without activation. Such 
a non-regulated interaction between Gc2 and the putative receptor may explain why the risk of cancer in Gc2-2 
homozygotes is decreased rather than  increased39. Thus, our results provide an intriguing clue to the possible 
role(s) of the glycan moiety in macrophage activation signaling.
Figure 5.  Purification of Gc proteins by vitamin D affinity column chromatography. CBB staining patterns of 
two independently prepared samples of Gc1F, purified with His-Trap column chromatography (A, Gc1F 1 and 
2) and blotting patterns with anti-Gc antibody (B, Gc1F 1 and 2). The eluate from the His-Trap column (A, 
Gc1F 1) was subjected to vitamin D affinity column chromatography. Affinity-purified Gc1F was detected by 
CBB staining (C). Gc1S and Gc2 were similarly purified and stained with CBB (D). The CBB staining pattern of 
mouse GcMAF purified by a single step of vitamin D affinity column chromatography (E). Full-length gels and 
blots are included in a Supplementary Fig. 4.
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Our present data indicate that Gc1 protein synthesized in ExpiCHO-S cells is almost entirely HPA-lectin-
reactive, suggesting that the newly synthesized Gc1 bears only the monosaccharide (GalNAc-Thr420), and the 
following extension reactions of the O-glycan do not occur. Although the underlying mechanism of produc-
tion of this truncated O-glycan is unknown, it seems likely that the step-by-step glycosylation process in the 
Golgi apparatus is altered in ExpiCHO-S cells. Several tumor cell lines show altered distribution or partial loss 
of O-glycosylation enzymes in the Golgi  apparatus42, and alteration of the O-glycan biosynthesis pathway(s) 
might occur similarly in ExpiCHO cells. Alternatively, Gc1 protein might undergo premature exit from an early 
compartment of the Golgi apparatus. Thus, our results provide an interesting future direction for further studies 
of the machinery of protein glycosylation and secretion.
In conclusion, we established methodology to produce biologically active GcMAF in large quantities by 
overexpressing Gc proteins in ExpiCHO-S cells under serum-free suspension culture conditions. Notably, the 
synthesized GcMAF can be purified in a single step by means of vitamin D affinity column chromatography. 
This simple protocol is expected to be suitable for large-scale production of high-quality GcMAF for functional 
analysis and clinical testing.
Materials and methods
Construction of Gc‑protein expression vectors. We obtained a double-stranded DNA encoding a 
fusion protein consisting of human Gc1F protein and a histidine tag (His) at the C-terminal site (Gc1F-His 
DNA) by using the Oligo-DNA production service of Invitrogen (Supplementary Fig. 1A). Some triplet codons 
were modified to accord with the codon usage rates in animal cells in order to maximize the efficiency of transla-
tion. Gc1F-His DNA was inserted into the TOPO cloning site of pcDNA3.4-TOPO Vector (Invitrogen) (termed 
pcDNA3.4-TOPOGc1F-His), in which the inserted Gc1F-His DNA is transcribed under the control of CMV pro-
moter (Supplementary Fig. 2). To design Gc1S-His DNA, the GAT codon for aspartic  acid416  (D416) was replaced 
with the GAG codon for glutamic acid  (E416) (termed pcDNA3.4-TOPOGc1S-His, Supplementary Fig. 1B-1). To 
design Gc2-His DNA, the ACC codon for  threonine420  (T420) was replaced with the AAG codon for lysine  (K420) 
(termed pcDNA 3.4-TOPOGc2-His) (Supplementary Fig. 1B-2)4–6. We also synthesized a mouse Gc expression 
Figure 6.  Phagocytosis assay of Gc proteins synthesized in ExpiCHO-S cells. Phagocytosis activation activity 
of vitamin D affinity column-purified GcMAF was analyzed. U937 cells were grown in RPMI-1640 medium 
and differentiated into macrophage-like cells by means of TPA treatment. (A) Differentiated U937 cells were 
exposed to Gc1F, Gc1S and Gc2 proteins for 3 h, and then Dynabeads were added to evaluate phagocytotic 
activity (average phagocytosis index: API). LPS (1 µg) was used as a positive control. (B) APIs of Gc-1F from 
ExpiCHO-S with a truncated structure (GalNAc-Thr420 type, positive control), Gc-1F from CHO with an 
elongated glycoform [Trisaccharide-Thr420 type, β-d-galactosidase (−) and Sialidase (−)] and Gc-1F from CHO 
with a truncated glycoform [GalNAc-Thr420 type, β-d-galactosidase (+) and sialidase (+)]. (C) Dose–response 
relationships for API of Gc1F (C-1), Gc1S (C-2) and Gc2 (C-3) from ExpiCHO-S. Values are mean ± standard 
deviation. The statistical significance of differences between control and treatment groups was determined by 
applying Dunnett’s test (*p < 0.05, **p < 0.01).
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plasmid (pcDNA3.4-TOPOmouse-Gc) (Supplementary Fig. 1C). Large amounts of these expression vector DNAs 
were prepared by using an EndoFree Plasmid Kit (QIAGEN 12362) according to the supplier’s protocol.
CHO cell culture and transfection of Gc1F‑His expression plasmid. Chinese hamster ovary cells 
(CHO) were cultured in F12 medium (GIBCO 11765) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS, Biowest S1820), 100 U/ml penicillin, and 100 μg/ml streptomycin (Sigma-Aldrich P4333) at 37 °C 
in a humidified atmosphere of 5%  CO2. Cells were cultured to approximately 80% confluence in 6-well culture 
plates. The pcDNA3.4-TOPOGc1F-His expression plasmid (2.5 μg) and Lipofectamine 2000 (15 μl) (ThermoFisher 
Scientific Co.) were added in 2 ml medium per well. The plates were incubated for 3 days, then the culture media 
and cells were harvested. The expression level and sugar modification of Gc1F-His were evaluated.
Culture of ExpiCHO‑S and Expi293‑F cells. ExpiCHO-S cells (ThermoFisher Scientific Co. ExpiCHO-S 
Cells, Catalog number: A29127) were suspension-cultured in 25 ml of serum-free ExpiCHO Expression medium 
in an incubator at 37 °C with a humidified atmosphere of 8%  CO2 in air on an orbital shaker platform rotating at 
125 rpm to a final density of 6 × 106 viable cells/ml. A Gc expression plasmid (15 μg) (pcDNA3.4-TOPOGc1F-His, 
pcDNA3.4-TOPOGc1S-His, pcDNA3.4-TOPOGc2-His or pcDNA3.4-TOPOmouse Gc) was diluted with 1.0 ml of Opti 
PRO SFM (ThermoFisher Scientific Co.) and mixed with 80 μl of ExpiFectamine CHO Reagent (ThermoFisher 
Scientific Co.), previously diluted with 920 μl of Opti PRO SFM. This mixture was incubated for 5 min at room 
temperature and added to the ExpiCHO-S cell culture flask. The cells were incubated overnight, then 150 μl of 
ExpiCHO Enhancer and 6 ml of ExpiCHO Feed (ThermoFisher Scientific Co.) were added, and suspension cul-
ture was continued for 6–8 days (according to the supplier’s protocol, cell culture can be continued for up to 14 
or 15 days). Then, we harvested the cells and media and analyzed the expression levels and sugar modifications 
of the Gc proteins.
Expi293F cells (ThermoFisher Scientific Co. Expi293F cells, Catalog number: A14528) were suspension-
cultured in 30 ml of Expi293 Expression medium in an incubator at 37 °C with a humidified atmosphere of 8% 
 CO2 in air on an orbital shaker platform rotating at 125 rpm to a level of 2.5 × 106 cells/ml with > 95% viability. 
Gc expression plasmids (30 μg) were diluted with 1.5 ml of Opti-MEM (ThermoFisher Scientific Co.) and mixed 
with 80 μl of Expifectamine 293 reagent (ThermoFisher Scientific Co.), previously diluted with Opti-MEM to 
1.5 ml. This mixture was incubated for 20 min at room temperature and then added to an Expi293-F cell culture 
flask. The cells were incubated under the conditions specified above and, after 18 h, 150 μl of Expifectamine 293 
Transfection Enhancer 1 and 1.5 ml of Expifectamine 293 Transfection Enhancer 2 (ThermoFisher Scientific 
Co.) were added to the flask. The cells and the media were harvested at 3 days post-transfection. The expression 
levels and sugar modifications of the produced Gc proteins were characterized.
Purification of Gc‑His proteins with a His‑Tag column. For the purification of histidine-tagged Gc 
proteins, we performed His Trap HP  (Ni2+ pre-charged) column chromatography (GE Healthcare Life Sciences) 
according to the manufacturer’s protocol. Briefly, (1) the His Trap HP column (5 ml) was washed with binding 
buffer (20 mM sodium phosphate, 150 mM NaCl and 20 mM imidazole pH 7.4), (2) the cell culture supernatant 
was adjusted to the composition and pH of the binding buffer and filtered through a 0.45 μm filter, and (3) the 
filtrate was applied to the column, which was washed with binding buffer and eluted with elution buffer (20 mM 
sodium phosphate, 150 mM NaCl and 500 mM imidazole pH 7.4). Desalting was done by dialysis against 50 mM 
sodium phosphate pH 7.0.
Assessment of cell proliferation and cell numbers. We determined the viable and total cell counts by 
means of the trypan-blue exclusion method. Cell suspensions were diluted with 0.5% trypan-blue solution and 
the cells were counted on a Neubauer hematocytometer.
Quantitation of total protein. Protein concentrations were determined with BCA Protein Assay Kit 
(Thermo Fisher 23227) or by measuring the absorbance at 280 nm.
Western blot analysis of Gc proteins and lectin blot for glycan moieties. The synthesized human 
Gc-His proteins were mixed with equal amounts of SDS sampling buffer (125 mM Tris–HCl pH 6.8, 4% SDS, 
60% glycerol, 10 mM EDTA, 0.1 M DTT, 0.01% BPB, 10% 2-mercaptoethanol) and heated at 90 °C for 2 min. 
Samples were electrophoresed on 5–20% SDS polyacrylamide gel (Nacalai tesque, Kyoto, Japan) and bands were 
transferred to PVDF membranes (Merck Millipore Ltd., ME) using a semi-dry blotting device. The blot was 
incubated at 4 °C overnight with anti-Gc antibody (Abcam, ab153922) or with anti-His-tag antibody (Abcam 
ab18184), previously diluted in a blocking buffer containing 5% skim milk in TBST (25 mM Tris–HCl pH 7.4, 
150 mM NaCl and 0.1% Tween 20). The primary antibodies, anti-DBP/Gc and anti-His-tag antibodies, were 
reacted with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (NA934, GE Healthcare) and anti-
mouse IgG (GE Healthcare, NA9310v), respectively, and visualized by use of an enhanced chemiluminescence 
detection system (ECL prime, Amersham Bioscience). Biotin-conjugated Helix pomatia (HPA) lectin for Tn 
(Sigma-Aldrich, L6512) was used to detect the GalNAc/Tn moiety as previously  reported37. In addition, biotin-
conjugated Vicia villosa (VVA) lectin for GalNAc/Tn (Vector Laboratories, B-1235), biotin-conjugated Maackia 
amurensis lectin II (MAL-II) for sialic acid/ STn/ST (Vector Laboratories, B-1265) and biotin-conjugated peanut 
(PNA) lectin for Gal-GalNAc/T disaccharide (GeneTex, BTX01507) were used to confirm the glycosylation of 
Gc1 and Gc2 proteins.
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Purification of Gc proteins by vitamin d‑sepharose column chromatography. The suspension-
culture supernatant or His-trap column eluate was applied to a 25(OH)D3-sepharose column prepared accord-
ing to Link et al.43. The column was washed with binding buffer (50 mM Tris–HCl, 1.5 mM EDTA, 150 mM NaCl 
and 0.1% Triton X-100 pH 7.4) and eluted with 6 M guanidine. For desalting, the eluate was dialyzed against 
10 mM sodium phosphate pH 7.4.
Phagocytosis assay. The phagocytosis activity of GcMAF was assayed according to the reported  method44 
with slight modifications. U937 cells (human myeloid leukemia cell line; KAC Co., Ltd., Ritto, Japan) were grown 
in RPMI-1640 medium (Gibco by Life Technologies, Grand Island, USA) supplemented with 10% (v/v) heat-
inactivated FBS (Gibco Life Technologies, Grand Island, USA) and penicillin–streptomycin (Sigma-Aldrich, 
USA) in a fully humidified 5%  CO2/95% air atmosphere at 37 °C. To induce differentiation into macrophage-like 
cells, 2.5 × 106 U937 cells seeded onto 10 cm culture dishes were treated with 10 ng/ml 12-O-tetra-decanoylphor-
bol-13-acetate (TPA) (Nacalai tesque Co., Ltd., Kyoto, Japan) for 3 days, washed with 3 ml of Dulbecco’s PBS 
(Gibco Life Technologies Grand Island, USA) twice, and then trypsinized (1 ml of trypsin–EDTA per 10 cm 
dish) for 2–3 min at 37 °C. Then 2.5 × 105 trypsinized cells were dispersed in 10% FBS/RPMI-1640 medium, lay-
ered onto cover-glasses in a 24-well plate, and treated with 10 ng/ml TPA for 3 days. These cells were incubated 
with serum-free RPMI-1640 medium for 15 h and pretreated with GcMAF for 3 h by replacing the medium 
with serum-free RPMI-1640 medium containing 10  ng/ml  GcMAF1f,  GcMAF1s, or  GcMAF2. LPS (1  µg/ml) 
was used as a positive control. After 3 h pretreatment, the medium was replaced by serum-free RPMI-1640 
medium containing 90 μg/ml protein G magnetic beads (Dynabeads Protein G; Invitrogen, Carlsbad, USA) and 
incubated for 1.5 h. The cover-glasses were washed with phosphate-buffered saline and the cells were fixed with 
methanol for 1 min. The fixed cells were air-dried, stained with Giemsa’s azur eosin methylene blue solution 
(Merck KGaA, Darmstadt, Germany) for 1 h and washed with distilled water. The cells were air-dried, and then 
immersed in Malinol (Muto Pure Chemicals Co., Ltd., Tokyo). Cells were imaged with an upright microscope 
(DM6B, Leica Microsystems, Germany); nine random areas in each cover-glass sample were examined. The 
activity of GcMAF was expressed as the average phagocytosis index (API), calculated according to the following 
formula: API = (number of internalized beads within the macrophages)/(number of macrophages within the 
photograph). We prepared three independent samples for each analysis and thus 27 areas (9 random areas × 3 
independent samples) were analyzed for each sample. The above examination was repeated twice.
Statistical analysis. All values are expressed as mean ± standard deviation. Statistical analyses were per-
formed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan)45, which is a graphical 
user interface for R (The R Foundation for Statistical Computing, Vienna, Austria); specifically, it is a modified 
version of R commander designed to add statistical functions frequently used in biostatistics. The statistical sig-
nificance of differences between control and treatment groups was determined by use of Dunnett’s test.
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